About VisionGateVisionGate, Inc. is developing a revolutionary non-invasive test for the early detection of lung cancer, using its automated 3D cell imaging platform, the Cell-CT™, which generates high-resolution 3D biosignatures from intact cells using a sputum sample. The company's LuCED™ test is initially being developed for adjunctive use with low dose x-ray computed tomography (CT) screening for the early detection of lung cancer in high risk individuals. Adjunctive use of LuCED to better manage the high rate of false positive results in CT screening could increase the utility and cost effectiveness of the approach, which has been shown to decrease lung cancer deaths in former and current smokers. For more information, visit www.visiongate3D.com.VisionGate
GendeLLindheim BioCom PartnersPresident
Barbara Lindheim or Jennifer Anderson+1 602 617-1237
+1 212 email@example.com
|SOURCE VisionGate, Inc.|
Copyright©2010 PR Newswire.
All rights reserved